Protagenic Therapeutics, Inc. Overview
Pro stress-test →Protagenic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class peptide-based treatments for stress-related neuropsychiatric disorders. The company completed a Phase 1 multiple-dose safety study showing a clean safety and tolerability profile and remains on track to begin Phase 2 enrollment in 2026 for lead candidate PT00114 targeting treatment-resistant depression and anxiety.
Strategic Profile
Pro stress-test →The company completed PT00114's Phase 1 multiple-dose safety and tolerability study and underwent a separation in March 2026, which removed over $6.3M in liabilities and more than $1M in annualized costs. The company appointed Bill Nichols Jr. as President to accelerate development of lead candidate PT00114, a first-in-class TCAP pathway neuropeptide therapy.
Competitive Landscape
Pro stress-test →Protagenic competes in the stress-related neuropsychiatric and CNS disorder treatment space. Direct competitors include larger biopharmaceutical companies developing treatments for treatment-resistant depression and anxiety, such as Perception Neuroscience (PTSD, depression), Janssen/J&J (esketamine), and other emerging neuropeptide-based therapies. The company's first-in-class TCAP pathway positioning provides differentiation, though success depends on navigating Phase 2/3 development and regulatory approval.
Industry Context
Protagenic Therapeutics, Inc. operates in CNS-targeted neuropeptide therapeutics.
Key facts
Founded: Unknown · Headquarters: New York, US · Employees: Unknown · Revenue: $0 (pre-revenue, clinical stage) · Market cap: $9.4M